RT Journal Article SR Electronic T1 Genetic surveillance of Plasmodium falciparum reveals rapid population changes following first-line treatment policy revisions in the Greater Mekong Subregion JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.06.06.24308535 DO 10.1101/2024.06.06.24308535 A1 Verschuuren, Tess D A1 Wasakul, Varanya A1 Thuy-Nhien, Nguyen A1 Booth, Ethan A1 Quang, Huynh Hong A1 Thang, Ngo Duc A1 Chindavongsa, Keobouphaphone A1 Sovannaroth, Siv A1 Banouvong, Virasak A1 Sengsavath, Viengphone A1 Mayxay, Mayfong A1 Tuyen, Nguyen Thi Kim A1 Phuong, Vo Ngoc Lam A1 Trung, Pham Duc A1 Gonçalves, Sónia A1 Chen, Soun A1 Phalivong, Sonexay A1 Xayvanghang, Saiamphone A1 Mahaphontrakoon, Supaporn A1 Pearson, Richard D A1 Newton, Paul N A1 Maude, Richard J A1 Ashley, Elizabeth A A1 Ariani, Cristina V A1 Simpson, Victoria J A1 Day, Nicholas P A1 Dondorp, Arjen M A1 Miotto, Olivo YR 2024 UL http://medrxiv.org/content/early/2024/06/07/2024.06.06.24308535.abstract AB Background Genetic surveillance of Plasmodium falciparum (Pf) is an important tool for tracking antimalarial resistant strains, informing decision-making by National Malaria Control Programmes (NMCPs). Here, we present an analysis of 5,754 samples collected by the GenRe-Mekong project, in collaboration with NMCPs in the Greater Mekong Subregion (GMS), powered by new user-friendly visualization tools developed to translate genomic data into accessible actionable information.Methods Samples collected from patients presenting at public health facilities between 2017 and 2022 were genotyped using the SpotMalaria platform. Output data included genotypes for markers of antimalarial resistance, and genetic barcodes for analysis of relatedness. We developed the grcMalaria R package, which allows users to specify sample selection criteria, and produce geographical maps of prevalence, diversity and relatedness. It also identifies circulating parasite clusters, characterizing their drug resistance profile and mapping their spread.Results Since 2020, a rapid reduction in Pf incidence was observed, alongside a decline of the KEL1/PLA1 lineage resistant to dihydroartemisinin-piperaquine (DHA-PPQ), previously dominant in the eastern GMS. The frequency of plasmepsin2/3 amplifications, associated with piperaquine resistance, dropped from 62% in 2017-2019 to 2% in the first half of 2022. This coincided with a switch in frontline therapy, away from DHA-PPQ, in Cambodia, Thailand, and Vietnam. Artemisinin resistance levels remained high, with a regional prevalence of 89% in 2022. No evidence of emerging mefloquine resistance was found.Conclusion Routine genetic surveillance of Pf can reveal changes in parasite populations in response to public health interventions, especially when its results are translated into intuitive graphical visualizations, providing actionable information for NMCPs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Bill & Melinda Gates Foundation and by The Global Fund to Fight AIDS, Tuberculosis and Malaria. This research was funded in part by the Wellcome Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approvals were obtained both from ethics committees in the country of collection, and from the Oxford Tropical Research Ethics Committee (OxTREC)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon request and will be made publicly available at https://github.com/GenRe-Mekong/Data upon publication in a peer reviewed journal.